299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00880100
(ClinicalTrials.gov)
April 20099/4/2009Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)Efficacy and Safety of Ultrase MT12 in the Control of Steatorrhea in Cystic Fibrosis (CF) and Pancreatic Insufficient (PI) Children Aged 2 to 6 Years OldCystic Fibrosis;Pancreatic InsufficiencyDrug: Ultrase® MT12Forest LaboratoriesNULLCompleted2 Years6 YearsAll49Phase 3United States
2NCT00513682
(ClinicalTrials.gov)
July 20077/8/2007Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA%) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)Cystic Fibrosis;Pancreatic InsufficiencyDrug: Ultrase® MT20Forest LaboratoriesNULLCompleted7 Years11 YearsAll9Phase 3United States
3NCT00408317
(ClinicalTrials.gov)
November 20064/12/2006Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase® MT20 to Placebo for the Correction of Steatorrhea in Patients With Cystic Fibrosis (CF)Cystic Fibrosis;Exocrine Pancreatic InsufficiencyDrug: Ultrase® MT20;Drug: PlaceboForest LaboratoriesNULLCompleted7 YearsN/AAll36Phase 3United States